Repair Impact Fund

Novo Holdings REPAIR Impact Fund invested €18 million in four companies developing anti-infective therapies in its first year and appointed Dr John H. Rex chairman of its Scientific Selection Board.

Novo Holdings has opened its investment proposal round to U.S. and Canadian life science companies for its anti-microbial resistance impact fund, REPAIR. The window for submissions will be open from 4 September to 11 October.

Today, the REPAIR Impact Fund opens its investment proposal round to European life science companies. Companies are invited to submit a non-confidential proposal, which will be evaluated during the spring. Successful projects will be invited to submit more extensive confidential proposals.

Camilla Hansen joined Novo Seeds in June of 2018.

Emmanuelle Coutanceau joined Novo A/S in September 2015 as Investment Director of Novo Seeds. She led the Series B investments in Corwave, and serves on the Boards of Adenium Biotech, Antag Therapeutics, Avilex Pharma, Corwave, Inthera Bioscience, MinervaX and Pcovery.

Organizationally, the REPAIR Impact Fund resides in Novo Holdings as a separate investment budget led by Seed Investments. This is the Novo Holdings team dedicated to the REPAIR Impact Fund.

Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Holdings Seed Investments.

The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.